Premium
Changes in the levels of house dust mite specific IgG 4 during immunotherapy in asthmatic children
Author(s) -
TSAI L. C.,
TANG R.B.,
HUNG M.W.,
CHANG Z.N.
Publication year - 1991
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.1991.tb01670.x
Subject(s) - medicine , immunotherapy , immunology , allergy , house dust mite , pyroglyphidae , antibody , immunoglobulin e , asthma , mite , subclass , placebo , immune system , biology , pathology , botany , alternative medicine
Summary Serum levels of IgG subclass and house dust mite ( Dermatophagoides pteronyssinus, Dpt ) specific IgG 4 were evaluated during immunotherapy in asthmatic children. Asthmatic children undergoing long‐term immunotherapy (more than 2 years) posed a mean value of total serum IgG 4 or Dpt ‐specific IgG 4 antibodies significantly higher than that of patients prior to receiving immunotherapy, asthmatic (placebo) controls, or patients undergoing short‐term immunotherapy (less than 1 year) ( P < 0.05). The mean levels of serum Dpt ‐specific IgG 4 in all asthmatic groups were also significantly higher than in the non‐allergic controls ( P < 0.01). Moreover, the mean level of Dpt ‐specific IgG 4 tended to increase during immunotherapy. A significant correlation between total serum IgG 4 and Dpt ‐specirk IgG 4 antibodies was noted ( r = 0.6243; P < 0.001). Serial follow‐up reveals that Dpt ‐specific IgG 4 levels usually rose significantly with clinical improvement in asthmatic children during immunoiherapy. These results suggest that the anti‐mite‐specific IgG 4 antibody may serve as an indicator for clinical outcome of mite allergy during immunotherapy.